Skip to main content

Advertisement

SpringerLink
Log in

Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

We summarized 16 controlled studies and evaluated the correlation of resveratrol supplementation with metabolic parameters such as the body weight, waist circumference (WC), systolic blood pressure (sbp), HDL, total cholesterol, triglyceride and glucose levels. This meta-analysis was carried out to determine the association between the resveratrol intake with metabolic parameters in metabolic syndrome patients. PubMed, Scopus, Cochrane and Google Scholar were searched from inception to December 2018 using relevant keywords. All articles were independently reviewed by two authors using predetermined selection criteria. We have selected the studies that investigated the effects of resveratrol on metabolic parameters. Of 16 studies, 10 were performed on human subjects, and in 6 studies animal models were used. Standard mean difference (SMD) with 95% confidence interval were determined using Der Simonian and Laird random-effects modeling, when there was a significant heterogeneity between studies. Funnel plot and Egger’s test were conducted to examine the risk of publication bias. Pooled effect sizes in human studies indicated a significant impact of resveratrol supplementation on glucose level [−1.73 (−2.99, −0.47); p = 0.007)] and WC [−1.73 (−2.79, −0.67); p = 0.001] compared with the control group. Also combining the results of studies on rat samples (n = 6), indicated significant effect of resveratrol on decreasing weight [−22.95 (−44.74, −1.17); p = 0.04], TGs [−6.76 (−11.10, −2.42); p = 0.001], sbp [−7.30 (−12.48, −2.13); p = 0.006], and it can influence significantly on increasing HDL level (4.75 (1.87, 7.63); p = 0.001). However, resveratrol was not significantly effective on total cholesterol in both samples. The results of subgroup analysis of human studies showed that resveratrol has significant effect on metabolic parameters (glucose level and WC) at the dosage of > 500 mg and with long-term interventions ≥ 10 weeks. Administration of resveratrol can meaningfully reduce the BW, WC, TGs, and glucose level, also it can increase HDL, but not total cholesterol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Abbreviations

BW:

body weight

WC:

waist circumference

sbp:

systolic blood pressure

HDL:

high density lipoprotein

TGs:

triglyceride

SMD:

standard mean difference

UCP :

uncoupling protein

SIRT1:

sirtuin-1

PGC-1α:

proliferator-activatedreceptor-gamma-coactivator1-α

C/EBPα:

CCAAT-enhancer-binding protein

PPAR:

peroxisome proliferator-activated receptors

Nrf2:

transcription factor nuclear factor-E2-related factor-2

RCT:

randomized controlled trial

BMI:

body mass index

AMPK:

adenosine monophosphate (AMP)-activated protein kinasee

TNF-α :

tumor necrosis factor-alpha

References

  1. Abete I, Goyenechea E, Zulet MA, Martinez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis. 2011;21(Suppl 2):B1–15. https://doi.org/10.1016/j.numecd.2011.05.001.

    Article  CAS  PubMed  Google Scholar 

  2. Lifshitz F, Lifshitz JZ. Globesity: the root causes of the obesity epidemic in the USA and now worldwide. Pediatr Endocrinol Rev. 2014;12(1):17–34.

    PubMed  Google Scholar 

  3. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29(1):29–48. https://doi.org/10.1093/epirev/mxm001.

    Article  PubMed  Google Scholar 

  4. Marti A, Martinez-Gonzalez MA, Martinez JA. Interaction between genes and lifestyle factors on obesity. Proc Nutr Soc. 2008;67(1):1–8. https://doi.org/10.1017/S002966510800596X.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. https://doi.org/10.1371/journal.pone.0042529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Alfaro FJ, Gavrieli A, Saade-Lemus P, Lioutas VA, Upadhyay J, Novak V. White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging. Metabolism. 2018;78:52–68. https://doi.org/10.1016/j.metabol.2017.08.009.

    Article  CAS  PubMed  Google Scholar 

  7. Farzaei MH, El-Senduny FF, Momtaz S, Parvizi F, Iranpanah A, Tewari D, et al. An update on dietary consideration in inflammatory bowel disease: anthocyanins and more. Expert Rev Gastroenterol Hepatol. 2018;12(10):1–18. https://doi.org/10.1080/17474124.2018.1513322.

    Article  CAS  Google Scholar 

  8. Naseri R, Farzaei F, Haratipour P, Nabavi SF, Habtemariam S, Farzaei MH, et al. Anthocyanins in the Management of Metabolic Syndrome: a pharmacological and biopharmaceutical review. Front Pharmacol. 2018;9:1310. https://doi.org/10.3389/fphar.2018.01310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Garcia-Conesa MT. Dietary polyphenols against metabolic disorders: how far have we progressed in the understanding of the molecular mechanisms of action of these compounds? Crit Rev Food Sci Nutr. 2017;57(9):1769–86. https://doi.org/10.1080/10408398.2014.980499.

    Article  CAS  PubMed  Google Scholar 

  10. Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M. Cinnamon, a promising prospect towards Alzheimer's disease. Pharmacol Res. 2018;130:241–58. https://doi.org/10.1016/j.phrs.2017.12.011.

    Article  CAS  PubMed  Google Scholar 

  11. Vors C, Couillard C, Paradis ME, Gigleux I, Marin J, Vohl MC, et al. Supplementation with resveratrol and curcumin does not affect the inflammatory response to a high-fat meal in older adults with abdominal obesity: a randomized, placebo-controlled crossover trial. J Nutr. 2018;148(3):379–88. https://doi.org/10.1093/jn/nxx072.

    Article  PubMed  Google Scholar 

  12. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–82. https://doi.org/10.1124/dmd.104.000885.

    Article  CAS  PubMed  Google Scholar 

  13. Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011;1215(1):40–7. https://doi.org/10.1111/j.1749-6632.2010.05845.x.

    Article  CAS  PubMed  Google Scholar 

  14. Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Arias N, Andres-Lacueva C, et al. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond). 2011;8(1):29. https://doi.org/10.1186/1743-7075-8-29.

    Article  CAS  Google Scholar 

  15. Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Churruca I, Portillo MP. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem. 2013;141(2):1530–5. https://doi.org/10.1016/j.foodchem.2013.03.085.

    Article  CAS  PubMed  Google Scholar 

  16. Aguirre L, Fernandez-Quintela A, Arias N, Portillo MP. Resveratrol: anti-obesity mechanisms of action. Molecules. 2014;19(11):18632–55. https://doi.org/10.3390/molecules191118632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fernandez-Quintela A, Milton-Laskibar I, Gonzalez M, Portillo MP. Antiobesity effects of resveratrol: which tissues are involved? Ann N Y Acad Sci. 2017;1403(1):118–31. https://doi.org/10.1111/nyas.13413.

    Article  CAS  PubMed  Google Scholar 

  18. Hu P, Zhao L, Chen J. Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr. 2015;54(4):569–79. https://doi.org/10.1007/s00394-014-0738-4.

    Article  CAS  PubMed  Google Scholar 

  19. Kang NE, Ha AW, Kim JY, Kim WK. Resveratrol inhibits the protein expression of transcription factors related adipocyte differentiation and the activity of matrix metalloproteinase in mouse fibroblast 3T3-L1 preadipocytes. Nutr Res Pract. 2012;6(6):499–504. https://doi.org/10.4162/nrp.2012.6.6.499.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kwon JY, Seo SG, Yue S, Cheng JX, Lee KW, Kim KH. An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. Nut Res (New York, NY). 2012;32(8):607–16. https://doi.org/10.1016/j.nutres.2012.06.014.

    Article  CAS  Google Scholar 

  21. Chen Y, Siegel F, Kipschull S, Haas B, Frohlich H, Meister G, et al. miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat Commun. 2013;4:1769. https://doi.org/10.1038/ncomms2742.

    Article  CAS  PubMed  Google Scholar 

  22. Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, Fulda S, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010;92(1):5–15. https://doi.org/10.3945/ajcn.2009.28435.

    Article  CAS  PubMed  Google Scholar 

  23. Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010;24(6):1997–2009. https://doi.org/10.1096/fj.09-142943.

    Article  CAS  PubMed  Google Scholar 

  24. Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015;1852(6):1145–54. https://doi.org/10.1016/j.bbadis.2014.10.013.

    Article  CAS  PubMed  Google Scholar 

  25. Javkhedkar AA, Quiroz Y, Rodriguez-Iturbe B, Vaziri ND, Lokhandwala MF, Banday AA. Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2015;308(10):R840–6. https://doi.org/10.1152/ajpregu.00308.2014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013;1832(10):1723–33. https://doi.org/10.1016/j.bbadis.2013.05.018.

    Article  CAS  PubMed  Google Scholar 

  27. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2018. https://doi.org/10.1016/j.cegh.2018.05.005.

  30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  32. van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One. 2015;10(3):e0118393. doi:0.1371/journal.pone.0118393.

    Google Scholar 

  33. Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12(10):497–501. https://doi.org/10.1089/met.2014.0082.

    Article  CAS  PubMed  Google Scholar 

  34. Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014;57:181–7. https://doi.org/10.1016/j.exger.2014.05.015.

    Article  CAS  PubMed  Google Scholar 

  35. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092–103 e1-6. https://doi.org/10.1016/j.cgh.2014.02.024.

    Article  CAS  PubMed  Google Scholar 

  36. Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nut Res (New York, NY). 2011;31(11):842–7. https://doi.org/10.1016/j.nutres.2011.09.028.

    Article  CAS  Google Scholar 

  37. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47(3):226–32. https://doi.org/10.1016/j.dld.2014.11.015.

    Article  CAS  PubMed  Google Scholar 

  38. Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum Sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018;37(3):223–33. https://doi.org/10.1080/07315724.2017.1392264.

    Article  CAS  PubMed  Google Scholar 

  39. Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102(5):1642–51. https://doi.org/10.1210/jc.2016-2160.

    Article  PubMed  Google Scholar 

  40. Martinez-Abundis E, Mendez-Del Villar M, Perez-Rubio KG, Zuniga LY, Cortez-Navarrete M, Ramirez-Rodriguez A, et al. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes. 2016;7(7):142–52. https://doi.org/10.4239/wjd.v7.i7.142.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–22. https://doi.org/10.1016/j.cmet.2011.10.002.

    Article  CAS  PubMed  Google Scholar 

  42. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–63. https://doi.org/10.1016/j.bcp.2008.11.027.

    Article  CAS  PubMed  Google Scholar 

  43. Peredo-Escarcega AE, Guarner-Lans V, Perez-Torres I, Ortega-Ocampo S, Carreon-Torres E, Castrejon-Tellez V, et al. The combination of resveratrol and quercetin attenuates metabolic syndrome in rats by modifying the serum fatty acid composition and by upregulating SIRT 1 and SIRT 2 expression in white adipose tissue. Evidence-based Complementary and Alternative Medicine : eCAM. 2015;2015:474032. https://doi.org/10.1155/2015/474032.

    Article  Google Scholar 

  44. Baek SH, Shin WC, Ryu HS, Lee DW, Moon E, Seo CS, et al. Creation of resveratrol-enriched rice for the treatment of metabolic syndrome and related diseases. PLoS One. 2013;8(3):e57930. https://doi.org/10.1371/journal.pone.0057930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sutra T, Oiry C, Azay-Milhau J, Youl E, Magous R, Teissedre PL, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008;56(24):11683–7. https://doi.org/10.1021/jf802357g.

    Article  CAS  PubMed  Google Scholar 

  46. Robich MP, Chu LM, Chaudray M, Nezafat R, Han Y, Clements RT, et al. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery. 2010;148(2):453–62. https://doi.org/10.1016/j.surg.2010.04.013.

    Article  PubMed  Google Scholar 

  47. Benrick A, Maliqueo M, Miao S, Villanueva JA, Feng Y, Ohlsson C, et al. Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:964070. https://doi.org/10.1155/2013/964070.

    Article  Google Scholar 

  48. Konings E, Timmers S, Boekschoten MV, Goossens GH, Jocken JW, Afman LA, et al. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int J Obes. 2014;38(3):470–3. https://doi.org/10.1038/ijo.2013.155.

    Article  CAS  Google Scholar 

  49. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21(11):851–6. https://doi.org/10.1016/j.numecd.2010.03.003.

    Article  CAS  PubMed  Google Scholar 

  50. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34(1):27–34. https://doi.org/10.1016/j.clnu.2014.03.009.

    Article  CAS  PubMed  Google Scholar 

  51. Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014;99(6):1510–9. https://doi.org/10.3945/ajcn.113.082024.

    Article  CAS  PubMed  Google Scholar 

  52. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71(12):822–35. https://doi.org/10.1111/nure.12081.

    Article  PubMed  Google Scholar 

  53. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22.

    Article  CAS  PubMed  Google Scholar 

  54. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42. https://doi.org/10.1038/nature05354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol. 2009;113(1–2):17–24. https://doi.org/10.1016/j.jsbmb.2008.11.001.

    Article  CAS  PubMed  Google Scholar 

  56. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1(1):35. https://doi.org/10.1038/s41698-017-0038-6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Davidov-Pardo G, Joye IJ, McClements DJ. Encapsulation of resveratrol in biopolymer particles produced using liquid antisolvent precipitation. Part 1: preparation and characterization. Food Hydrocoll. 2015;45:309–16. https://doi.org/10.1016/j.foodhyd.2014.11.023.

    Article  CAS  Google Scholar 

  58. Farzaei MH, Rahimi R, Nikfar S, Abdollahi M. Effect of resveratrol on cognitive and memory performance and mood: a meta-analysis of 225 patients. Pharmacol Res. 2018;128:338–44. https://doi.org/10.1016/j.phrs.2017.08.009.

    Article  CAS  PubMed  Google Scholar 

  59. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8):1169–76. https://doi.org/10.1002/mnfr.201100117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys. 2012;527(2):67–73. https://doi.org/10.1016/j.abb.2012.06.004.

    Article  CAS  PubMed  Google Scholar 

  61. Ajazuddin AA, Qureshi A, Kumari L, Vaishnav P, Sharma M, et al. Role of herbal bioactives as a potential bioavailability enhancer for active pharmaceutical ingredients. Fitoterapia. 2014;97:1–14. https://doi.org/10.1016/j.fitote.2014.05.005.

    Article  CAS  PubMed  Google Scholar 

  62. Nabavi SF, Russo GL, Daglia M, Nabavi SM. Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem. 2015;179:305–10. https://doi.org/10.1016/j.foodchem.2015.02.006.

    Article  CAS  PubMed  Google Scholar 

  63. Arzola-Paniagua MA, Garcia-Salgado Lopez ER, Calvo-Vargas CG, Guevara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: a randomized controlled trial. Obesity (Silver Spring). 2016;24(7):1454–63. https://doi.org/10.1002/oby.21523.

    Article  CAS  Google Scholar 

  64. Yun JW. Possible anti-obesity therapeutics from nature--a review. Phytochemistry. 2010;71(14–15):1625–41. https://doi.org/10.1016/j.phytochem.2010.07.011.

    Article  CAS  PubMed  Google Scholar 

  65. Bruckbauer A, Zemel MB. Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes. 2013;6:93–102. https://doi.org/10.2147/DMSO.S40840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

    Sedigheh Asgary

  2. Epidemiology and Biostatistics Department, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

    Raheleh Karimi

  3. Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    Raheleh Karimi

  4. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran

    Saeideh Momtaz

  5. Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran

    Saeideh Momtaz

  6. Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Rozita Naseri

  7. Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Mohammad Hosein Farzaei

Authors
  1. Sedigheh Asgary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raheleh Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saeideh Momtaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rozita Naseri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Hosein Farzaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Hosein Farzaei.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asgary, S., Karimi, R., Momtaz, S. et al. Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis. Rev Endocr Metab Disord 20, 173–186 (2019). https://doi.org/10.1007/s11154-019-09494-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-019-09494-z

Keywords

Search

Navigation